Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zoan Nuáil Teoranta is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is under the review of 1 distinct examiner, representing the company's total current workload at the patent office. The applicant's immediate focus is on this single pending matter to advance their patent position.
The prosecution is localized in 1 distinct art unit, which indicates a specific technical area of interest for the 1 pending office action. RAHMAN, MASUDUR is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. As the only examiner involved, RAHMAN, MASUDUR is the individual whose interpretation will determine the outcome of the current filing.
A practitioner can dedicate all efforts to understanding the specific requirements of RAHMAN, MASUDUR. With only 1 distinct examiner and 1 distinct art unit, the prosecution process is streamlined and lacks the complexity of larger portfolios. The 1 pending office action in Biotechnology & Pharmaceuticals is the sole active point of engagement for Zoan Nuáil Teoranta at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18840894 | CORAL BIOINKS | RAHMAN, MASUDUR | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840894 | CORAL BIOINKS | RAHMAN, MASUDUR | 1633 | §103 | Non-Final OA | — | Pending | Aug 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZoan Nuáil Teoranta has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Masudur Rahman has the most, with 1 of Zoan Nuáil Teoranta's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
